췌장암 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• Pancreatic cancer is one of the most lethal cancers throughout the globe and majorly affects men compared to women. Pancreatic cancer types can be divided into two larger categories: exocrine pancreatic cancer, which includes adenocarcinoma, and neuroendocrine pancreatic cancer.
• The United States accounts for the largest market size (around 50%) of pancreatic cancer, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• Among the approved therapies, LYNPARZA (olaparib) is expected to garner the highest market share in the United States.
• For pancreatic cancer patients showing BRCA mutations, LYNPARZA (olaparib) was approved by the US FDA in 2019. VITRAKVI (larotrectinib) and ROZLYTREK (entrectinib) are approved for solid tumor patients having NTRK gene expression. Other than these, KEYTRUDA (pembrolizumab) is approved for solid tumor patients having microsatellite instability-high expression.
• In January 2024, Alligator Bioscience announced positive top-line results from the OPTIMIZE-1 Phase II study of the company's lead asset mitazalimab in first line metastatic pancreatic cancer.
• The study achieved its primary endpoint demonstrating a confirmed objective response rate (ORR) of 40.4%, an unconfirmed ORR of 50.9% and a disease control rate (DCR) of 79% in 57 evaluable patients, as per the response evaluation criteria in solid tumors.
• The development pipeline for pancreatic cancer is robust, with significant involvement from key players like Alligator Bioscience, Actuate Therapeutics, and other companies advancing into mid-stage clinical trials.

DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of pancreatic cancer, historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Pancreatic cancer market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM pancreatic cancer market size from 2022 to 2036. The report also covers current pancreatic cancer treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Factors Driving the Growth of the Pancreatic Cancer Market

Rising Pancreatic Cancer Incidence

According to DelveInsight's analysis, the total number of incident cases of pancreatic cancer in the US was approximately ~63,700 in 2025.

Role of Immune Checkpoint Inhibitors in PDAC

The potential of immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapies, is being explored in PDAC. Clinical trials combining immunotherapy with other treatment modalities (e.g., chemotherapy, radiation, or targeted therapies) may increase efficacy and open new treatment pathways.

Advancing Precision Medicine for Pancreatic Cancer

Novel strategies, including RAS-directed therapies and advanced immunotherapies, are being developed to more effectively tackle pancreatic cancer. These approaches offer hope for improved survival and quality of life by targeting cancer more precisely.

Advancing PDAC Treatment Through Targeted and Combination Approaches

The development of new targeted therapies, such as KRAS inhibitors (like Daraxonrasib) or epigenetic modulators, provides an opportunity to treat PDAC based on specific genetic mutations or tumor characteristics. Additionally, combination therapies, which pair existing treatments with newer agents, offer an opportunity to overcome resistance and enhance therapeutic effectiveness.

Emergence of Novel Pancreatic Cancer Drugs

The pancreatic cancer treatment pipeline for metastatic or unresectable pancreatic cancer includes LOAd703 (Lokon Pharma), OT-101 (Oncotelic), Daraxonrasib (Revolution Medicines) (first-line treatment), and Optune (Novocure). In the adjuvant or neoadjuvant setting, therapies under development include Daraxonrasib for resectable PDAC, BNT122 (BioNTech and Genentech), and ELI-002 (Elicio Therapeutics) for patients with high relapse-risk mKRAS+ PDAC.

Emerging KRAS-Targeted Therapies in Pancreatic Cancer

There are multiple KRAS-targeting drugs in development for pancreatic cancer, including HRS-4642 (Jiangsu Hengrui Pharmaceuticals) (with gemcitabine/nab-paclitaxel) for neoadjuvant/adjuvant use, TSN1611 (Tyligand Pharmaceuticals (Suzhou)) for KRAS G12D-mutated tumors, Glecirasib (Jacobio Pharmaceuticals) (JAB-21822) for KRAS G12C-mutated advanced cancers, and others.

Pancreatic Cancer Treatment Market

Pancreatic Cancer Overview, Country-Specific Treatment Guidelines and Diagnosis

Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. The pancreas release enzymes that aid digestion and produces hormones that help manage blood sugar. Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Several types of growth can occur in the pancreas, including cancerous and noncancerous tumors. The most common type of cancer that forms in the pancreas begins in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma).

Diagnosing pancreatic cancer involves a medical history review, physical examination, and imaging tests like CT scan, MRI, and endoscopic ultrasound. Biopsy procedures such as fine needle aspiration (FNA) or surgical biopsy confirm cancer presence. Blood tests and additional imaging like PET scan may also be used to assess cancer spread and guide treatment decisions.

The pancreatic cancer report provides an overview of pancreatic cancer pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient's journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Pancreatic Cancer Treatment

About 20% of people diagnosed with pancreatic cancer can have surgery because most pancreatic cancers are found after the disease has already spread. Surgery for pancreatic cancer may be combined with systemic therapy and/or radiation therapy. Typically, these additional treatments are given after surgery, which is called adjuvant therapy. However, systemic therapy and/or radiation therapy may sometimes be used before surgery to shrink a tumor, and this is called neoadjuvant therapy or preoperative therapy.

The chemotherapy drugs used for the treatment of pancreatic cancer include XELODA (capecitabine), 5-FU (fluorouracil), GEMZAR (gemcitabine), CAMPTOSAR (irinotecan), and others.

Targeted therapies such as TARCEVA (erlotinib) was approved by the FDA for people with advanced pancreatic cancer in combination with the chemotherapy drug gemcitabine. Another drug, LYNPARZA (olaparib) is approved for people with metastatic pancreatic cancer associated with a germline (hereditary) BRCA mutation.

Pancreatic Cancer Epidemiology

The pancreatic cancer epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2026 to 2036. The pancreatic cancer epidemiology is segmented with detailed insights into Total Incident Cases, Molecular Alteration-specific, and Stage-specific Cases of Pancreatic Cancer.

• As per DelveInsight estimates, exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer accounting for more than 90% of total cases.
• According to DelveInsight's analysis, the total number of incident cases of pancreatic cancer in the US was approximately ~63,700 in 2025.
• According to the analysis, in the US, the majority of pancreatic cancer cases in 2025 were diagnosed at a distant stage (50%), followed by regional (37%) and localized stages (13%), highlighting a concerning trend of late-stage detection.

Pancreatic Cancer Recent Developments

• In March 2026, Revolution Medicines announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline including daraxonrasib will be featured at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
• In February 2026, Novocure announced that the U.S. Food and Drug Administration (FDA) approved OPTUNE Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.
• In January 2026, ChipScreen Biosciences received regulatory approval from China's National Medical Products Administration (NMPA) to initiate a new clinical trial for chiauranib in pancreatic cancer, marking a key advancement following encouraging earlier data.
• In October 2025, the US FDA has granted Orphan Drug Designation (ODD) to daraxonrasib, for the treatment of pancreatic cancer.
• In September 2025, Revolution Medicines announced key clinical updates from its Phase I trials of daraxonrasib, supporting the initiation of RASolute-303, a global Phase III registrational study evaluating daraxonrasib as a first-line treatment for metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Pancreatic Cancer Drug Chapters

The drug chapter segment of the pancreatic cancer report encloses a detailed analysis of pancreatic cancer marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the pancreatic cancer pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Pancreatic Cancer Marketed Drugs

LYNPARZA (olaparib): AstraZeneca

LYNPARZA (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumors harboring a deficiency in homologous recombination repair, such as mutations in BRCA1 and/or BRCA2. In December 2019, AstraZeneca announced that LYNPARZA (olaparib) had been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works upon increasing the ability of the body's immune system to help detect and fight tumor cells. In May 2017, Merck announced that the US FDA had approved KEYTRUDA (pembrolizumab) to treat adult and pediatric patients with unrespectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Pancreatic Cancer Emerging Drugs

Daraxonrasib (RMC-6236): Revolution Medicines

Daraxonrasib, a RAS (ON) multi-selective inhibitor, is designed as an oral, RAS-selective tri-complex inhibitor of multiple RAS (ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions. Daraxonrasib inhibits all three major RAS isoforms, suppressing the mutant cancer driver and cooperating wild-type RAS proteins.

The drug is currently being evaluated in the Phase III RASolute-302 trial (NCT06625320) for patients with previously treated metastatic PDAC, with clinical results expected in H1 2026.

Chiauranib (CS2164): ChipScreen Biosciences

Chiauranib (CS2164), developed by ChipScreen Biosciences, is an orally available, first-in-class triple-pathway kinase inhibitor being evaluated for locally advanced PDAC. The drug targets Aurora B, VEGFR/PDGFR/c-Kit, and CSF1R, thereby exerting anti-proliferative, anti-angiogenic, and immunomodulatory effects that may help overcome the highly aggressive and immunosuppressive tumor microenvironment characteristic of pancreatic tumors. Currently, the drug is being evaluated in Phase II clinical trial.

As of July 2025 follow-up, the chiauranib-based combination regimen demonstrated a 6-month progression-free survival (PFS) rate of approximately 80% in the first-line setting. This compares favorably to historical outcomes with standard chemotherapy (44%-56.4% in non-head-to-head comparisons), suggesting promising antitumor activity along with a manageable safety profile.

BNT122 (RO7198457/autogene cevumeran): BioNTech/Genentech

BNT122 is an mRNA cancer vaccine candidate for individualized neoantigen-specific immunotherapy being developed in collaboration with Genentech. It is being evaluated in ongoing Phase II (NCT05968326) trials in combination with atezolizumab followed by standard-of-care chemotherapy (mFOLFIRINOX) in patients with resected adjuvant resected PDAC compared to chemotherapy alone is ongoing. Currently, the drug is being evaluated in Phase II clinical trial.

As per company's 2026 corporate presentation, the data from Phase II final analysis is expected in 2027.

In February 2025, longer-term follow-up data from the Phase I trial in PDAC were published in Nature journal.

Pancreatic Cancer Market Outlook

• DelveInsight estimates that the United States holds the largest market share in 2025 among the 7MM. Chemotherapy regimens remain the dominant standard of care in first-line pancreatic cancer treatment.
• The total market size of pancreatic cancer is expected to increase in the 7MM during the forecast period driven by ongoing clinical research and better diagnostic tools which might improve the prognosis of the disease.

Pancreatic Cancer Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2026-2036, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Pancreatic Cancer Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for pancreatic cancer emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Duke University School of Medicine, Gustave Roussy Institute of Oncology, Heidelberg University Hospital, the University of Texas MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of pancreatic cancer. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated. One of the most important primary endpoints were overall survival (OS), progression-free survival (PFS), and overall response rate (ORR).

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

LYNPARZA (olaparib)

Medicare covers 100% of medicare prescription drug plans, and in the post-deductible stage, the patient needs to pay their co-pay part, and their plan will cover the rest of the drug cost. The co-pay part which needs to be paid by the patient ranges from USD 28 to USD 129.

KEYTRUDA (pembrolizumab)

Patients with Medicare may or may not have to pay a portion of the cost of KEYTRUDA (pembrolizumab) based on their insurance plan. For example, with a Medicare Advantage plan, 41% of patients had no out-of-pocket costs for the 200 mg dose of KEYTRUDA. Roughly 80% of patients responsible for a portion of the cost paid between USD 0 and USD 925 per infusion after meeting their deductible. Most patients with Medicaid typically pay USD 4-USD 8 per KEYTRUDA infusion. The co-pay part which needs to be paid by the patient ranges from USD 12,045.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of pancreatic cancer, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the pancreatic cancer market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM pancreatic cancer market.

Pancreatic Cancer Report Insights

• Pancreatic Cancer Patient Population
• Pancreatic Cancer Therapeutic Approaches
• Pancreatic Cancer Pipeline Analysis
• Pancreatic Cancer Market Size and Trends
• Existing and Future Market Opportunity

Pancreatic Cancer Report Key Strengths

• Eleven-year Forecast
• 7MM Coverage
• Pancreatic Cancer Epidemiology Segmentation
• Inclusion of Country Specific Treatment Guidelines
• KOL's Feedback On Approved and Emerging Therapies
• Key Cross Competition
• Conjoint Analysis
• Pancreatic Cancer Drugs Uptake
• Key Pancreatic Cancer Market Forecast Assumptions

Pancreatic Cancer Report Assessment

• Current Pancreatic Cancer Treatment Practices
• Pancreatic Cancer Unmet Needs
• Pipeline Product Profiles
• Pancreatic Cancer Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Pancreatic Cancer Market Drivers
• Pancreatic Cancer Market Barriers

FAQs:

• What is the growth rate of the 7MM pancreatic cancer treatment market?
• What was the pancreatic cancer total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like in 2036? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of pancreatic cancer?
• How many companies are developing therapies for the treatment of pancreatic cancer?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the pancreatic cancer market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Pancreatic Cancer-Market Overview at a Glance

• 3.1. Market Share (%) Pancreatic Cancer by Therapies in 2022
• 3.2. Market Share (%) of Pancreatic Cancer by Therapies in 2036

4. Executive Summary of Pancreatic Cancer

5. Key Events

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Types of Pancreatic Cancer
• 6.3. Stages of Pancreatic Cancer
• 6.4. Signs and Symptoms
• 6.5. Risk Factors and Causes
• 6.6. Pathophysiology/Mechanisms
• 6.7. Carcinogenesis and Molecular Biology
• 6.8. Molecular Genetics of Pancreatic Cancer
• 6.9. Diagnosis
  • 6.9.1. Differential Diagnosis
  • 6.9.2. Diagnostic Algorithm
  • 6.9.3. Diagnostic Guidelines
    • 6.9.3.1. ASGE Guideline on Screening for Pancreatic Cancer in Individuals With Genetic Susceptibility, 2022
    • 6.9.3.2. Metastatic Pancreatic Cancer: ASCO Guideline, 2020
    • 6.9.3.3. National Institute for Health and Care Excellence, NICE, 2022
    • 6.9.3.4. Clinical Practice Guidelines for Diagnosis of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM), 2020
    • 6.9.3.5. Clinical Practice Guidelines for Pancreatic Cancer 2019 from the Japan Pancreas Society
• 6.10. Treatment and Management
  • 6.10.1. Treatment Options by Pancreatic Cancer Stage
  • 6.10.2. Treatment Algorithm
  • 6.10.3. Treatment Guidelines for Pancreatic cancer
    • 6.10.3.1. NCCN Guidelines for the Treatment of Pancreatic Adenocarcinoma, 2022
    • 6.10.3.2. Metastatic Pancreatic Cancer: ASCO Guideline, 2020
    • 6.10.3.3. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
    • 6.10.3.4. Clinical Practice Guidelines for Diagnosis of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM), 2020
    • 6.10.3.5. Clinical Practice Guidelines for Pancreatic Cancer 2019 from the Japan Pancreas Society

7. Methodology

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale 7MM
• 8.3. Total Incident Cases of Pancreatic Cancer in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of Pancreatic Cancer in the United States
  • 8.4.2. Molecular Alteration-specific Incident Cases of Pancreatic Cancer in the United States
  • 8.4.3. Stage-specific Incident Cases of Pancreatic Cancer in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of Pancreatic Cancer in EU4 and the UK
  • 8.5.2. Molecular Alteration-specific Incident Cases of Pancreatic Cancer in EU4 and the UK
  • 8.5.3. Stage-specific Incident Cases of Pancreatic Cancer in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Incident Cases of Pancreatic Cancer in Japan
  • 8.6.2. Molecular Alteration-specific Incident Cases of Pancreatic Cancer in Japan
  • 8.6.3. Stage-specific Incident Cases of Pancreatic Cancer in Japan

9. Patient Journey

10. Marketed Therapies

• 10.1. Key-cross
• 10.2. LYNPARZA (olaparib): AstraZeneca
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activity
  • 10.2.4. Clinical Developmental Activities
    • 10.2.4.1. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Clinical Developmental Activities
    • 10.3.4.1. Clinical Trials Information
  • 10.3.5. Safety and Efficacy

11. Emerging Therapies

• 11.1. Key-cross
• 11.2. Mitazalimab (ADC-1013): Alligator Bioscience
  • 11.2.1. Product description
  • 11.2.2. Other developmental activity
  • 11.2.3. Clinical developmental activities
  • 11.2.4. Clinical trials information
• 11.3. Elraglusib (9 ING 41): Actuate Therapeutics
  • 11.3.1. Product description
  • 11.3.2. Other developmental activity
  • 11.3.3. Clinical developmental activities
  • 11.3.4. Clinical trials information
  • 11.3.5. Safety and efficacy

12. Pancreatic Cancer: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
• 12.5. Total Market Size of Pancreatic Cancer in the 7MM
• 12.6. Market Size of Pancreatic Cancer by Therapies in the 7MM
• 12.7. Market Size of Pancreatic Cancer in the United States
  • 12.7.1. Total Market size of Pancreatic Cancer in the United States
  • 12.7.2. Market Size of Pancreatic Cancer by Therapies in the United States
    • 12.7.2.1. Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in the United States
    • 12.7.2.2. Market Size of Pancreatic Cancer by Therapies (First-line) in the United States
    • 12.7.2.3. Market Size of Pancreatic Cancer by Therapies (Second-line plus) in the United States
• 12.8. Market Size of Pancreatic Cancer in EU4 and the UK
  • 12.8.1. Total Market Size of Pancreatic Cancer in EU4 and the UK
  • 12.8.2. Market Size of Pancreatic Cancer by Therapies in EU4 and the UK
    • 12.8.2.1. Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in EU4 and the UK
    • 12.8.2.2. Market Size of Pancreatic Cancer by Therapies (First-line) in EU4 and the UK
    • 12.8.2.3. Market Size of Pancreatic Cancer by Therapies (Second-line plus) in EU4 and the UK
• 12.9. Market Size of Pancreatic Cancer in Japan
  • 12.9.1. Total Market Size of Pancreatic Cancer in Japan
  • 12.9.2. Market Size of Pancreatic Cancer by Therapies in Japan
    • 12.9.2.1. Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in Japan
    • 12.9.2.2. Market Size of Pancreatic Cancer by Therapies (First-line) in Japan
    • 12.9.2.3. Market Size of Pancreatic Cancer by Therapies (Second-line plus) in Japan

13. Market Access and Reimbursement

• 13.1. Reimbursement
• 13.2. Key HTA Decisions
• 13.3. Patient Access Program

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

• 17.1. Report Methodology
• 17.2. Bibliography

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight